Discontinued — last reported Q4 '25
Chubb Interest Paid decreased by 3.6% to $189.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 29.5%, from $146.00M to $189.00M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 7.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $181.00M | $45.00M | $176.00M | $85.00M | $205.00M | $49.00M | $213.00M | $99.00M | $207.00M | $39.00M | $208.00M | $112.00M | $204.00M | $99.00M | $184.00M | $146.00M | $204.00M | $104.00M | $196.00M | $189.00M |
| QoQ Change | — | -75.1% | +291.1% | -51.7% | +141.2% | -76.1% | +334.7% | -53.5% | +109.1% | -81.2% | +433.3% | -46.2% | +82.1% | -51.5% | +85.9% | -20.7% | +39.7% | -49.0% | +88.5% | -3.6% |
| YoY Change | — | — | — | — | +13.3% | +8.9% | +21.0% | +16.5% | +1.0% | -20.4% | -2.3% | +13.1% | -1.4% | +153.8% | -11.5% | +30.4% | +0.0% | +5.1% | +6.5% | +29.5% |